Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Prednisolone, Rituximab, Vincristine in patients with Non-Hodgkin Lymphoma.
This statement is based on a regulatory approval from the Health Service Executive:
First line treatment of patients with low grade B cell Non Hodgkin's lymphoma (NHL). Rituximab to be included in CD20 positive patients.